Document Detail

ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs.
MedLine Citation:
PMID:  12776869     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The aim of this study was to determine if the stable antiarrhythmic peptide (AAP) analogue ZP123 increases gap junctional intercellular conductance and prevents reentrant ventricular tachycardia (VT) during coronary artery occlusion. METHODS AND RESULTS: Voltage clamp experiments demonstrated that 10 nM ZP123 improved gap junctional intercellular conductance by 69% +/- 20% in pairs of guinea pig ventricular myocytes. VT was induced by programmed stimulation in alpha-chloralose anaesthetized open chest dogs 1 to 4 hours after coronary artery occlusion. Three-dimensional activation mapping was done using six bipolar electrograms on each of 23 multipolar needles in the risk zone. When VT was reproducibly induced, dogs were randomly assigned to receive either saline or ZP123 cumulatively at three dose levels (intravenous bolus followed by 30-min infusion per dose). Attempts to induce VT were repeated in each infusion period. Mass spectrometry was used to measure ZP123 plasma concentrations. Twenty-six dogs with reentrant VT were included. ZP123 significantly prevented reentrant VT at all plasma concentrations vs saline: 1.0 +/- 0.2 nM: 6/12 vs 0/12; 7.7 +/- 0.6 nM: 7/13 vs 1/12; and 69.2 +/- 5.4 nM: 9/13 vs 1/13. The preventive effect of ZP123 on reentrant VT was closely correlated to reversal of functional, unidirectional conduction block. ZP123 did not affect effective refractory period, surface ECG parameters, mean arterial pressure, or infarct size. CONCLUSION: The stable AAP analogue ZP123 increased gap junctional intercellular conductance and specifically prevented the induction of reentrant VT during ischemia in a broad dose range without proarrhythmic or hemodynamic side effects. ZP123 is a promising candidate for use in preventing ischemia-induced VT.
Dezhi Xing; Anne Louise Kjølbye; Morten S Nielsen; Jørgen S Petersen; Kenneth W Harlow; Niels-Henrik Holstein-Rathlou; James B Martins
Related Documents :
12439369 - Primary and secondary prevention of sudden cardiac death: the role of the implantable c...
3342489 - Resetting of ventricular tachycardia with electrocardiographic fusion: incidence and si...
15118299 - Gitelman's syndrome with exercise-induced ventricular tachycardia.
2580279 - Activation of the right ventricular apical electrogram during ventricular tachycardia: ...
6170769 - Identification of the site of origin of ventricular premature beats and its activation ...
17954399 - Site-specific twelve-lead ecg features to identify an epicardial origin for left ventri...
23132179 - Perioperative management of pheochromocytoma and catecholamine-induced dilated cardiomy...
11123219 - Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction ...
23738919 - Non-invasive determination of atrial fibrillation cycle length by atrial color tissue d...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular electrophysiology     Volume:  14     ISSN:  1045-3873     ISO Abbreviation:  J. Cardiovasc. Electrophysiol.     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-06-02     Completed Date:  2003-10-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9010756     Medline TA:  J Cardiovasc Electrophysiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  510-20     Citation Subset:  IM    
Department of Internal Medicine, University of Iowa College of Medicine and VA Medical Center, Iowa City, Iowa 52242, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / physiology
Cell Membrane / drug effects,  metabolism
Disease Models, Animal
Dose-Response Relationship, Drug
Gap Junctions / drug effects*
Heart Block / metabolism,  physiopathology,  prevention & control
Heart Conduction System / drug effects,  metabolism,  physiopathology
Infusions, Intravenous
Models, Cardiovascular
Myocardial Ischemia / metabolism,  physiopathology*
Myocytes, Cardiac / drug effects,  ultrastructure
Oligopeptides / administration & dosage,  pharmacology,  therapeutic use*
Reproducibility of Results
Statistics as Topic
Tachycardia, Ventricular / metabolism,  physiopathology*,  prevention & control*
Reg. No./Substance:
0/Oligopeptides; 355151-12-1/rotigaptide; 81771-37-1/antiarrhythmic peptide
Comment In:
J Cardiovasc Electrophysiol. 2003 May;14(5):521-3   [PMID:  12776870 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart...
Next Document:  Use of electrogram characteristics during sinus rhythm to delineate the endocardial scar in a porcin...